Aprea Therapeutics (APRE) vs CNS Pharmaceuticals (CNSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CNS Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | CNSP |
|---|---|---|
| Share price | $0.5582 | $5.35 |
| Market cap | $7.03M | $7.82M |
| 1-day change | -7.74% | -1.47% |
| EPS (TTM) | $-0.95 | $-17.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $10.54 |
| 52-week low | $0.548 | $1.90 |
| Distance from 52-week high | -66.97% | -49.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +568.22% | +86.92% |
| Average volume | 280.14K | 6.40K |
| Shares outstanding | 12.59M | 1.46M |
| Employees | 8 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
APRE vs CNSP FAQ
Which is bigger, Aprea Therapeutics or CNS Pharmaceuticals?
CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $7.82M compared with $7.03M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and CNS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.